Jim Cramer: This Financial Stock Is A Buy, Core Scientific Is A 'Very Overvalued Situation'
Jim Cramer: This Financial Stock Is A Buy, Core Scientific Is A 'Very Overvalued Situation'
On CNBC's "Mad Money Lightning Round," Jim Cramer recommended buying Ally Financial Inc. (NYSE:ALLY).
Jim Cramer推薦買入Ally Financial Inc. (紐交所:ALLY)。
On July 17, Ally Financial posted stronger-than-expected quarterly earnings results.
7月17日，Ally Financial發佈了超出預期的季度業績報告。
Cramer said he is going to hold off from recommending Snowflake Inc. (NYSE:SNOW). "It's kind of like the long knives are out for those guys right now," he added.
Cramer表示，他將暫時不推薦Snowflake Inc. (紐交所:SNOW)。他補充道：「目前爲止，有點像持有對他們的長刀。」
On Aug. 15, Wells Fargo analyst Michael Turrin downgraded the rating for Snowflake from Overweight to Equal-Weight and lowered the price target from $200 to $130.
8月15日，富國銀行分析師邁克爾·特林將Snowflake的評級從超重降至等重，並將價格目標從200美元下調至130美元。
When asked about Royalty Pharma plc (NASDAQ:RPRX), he said, "I always thought there was going to be more to this stock than there has been. It's really been a bit of a bust."
當被問及Royalty Pharma plc (納斯達克：RPRX)時，他說：「我一直認爲這隻股票會比現在好得多。它真的有點失敗了。」
On Aug. 8, Royalty Pharma reported worse-than-expected second-quarter financial results. The company reported quarterly earnings of 96 cents per share which missed the analyst consensus estimate of 99 cents per share. The company reported quarterly sales of $537.00 million which missed the analyst consensus estimate of $628.26 million.
8月8日，Royalty Pharma報告了比預期更糟糕的第二季度財務業績。公司報告每股收益爲96美分，低於每股99美分的分析師共識預期。公司報告季度銷售額爲5,370萬美元，低於分析師共識預期的6,282.6萬美元。
Core Scientific, Inc. (NASDAQ:CORZ) is a "very overvalued situation, principally because of the fact that it's never made any money. But it is another play on crypto. If you like crypto, buy crypto."
Core Scientific，Inc. (納斯達克:CORZ)是一個「非常被高估的情況，主要是因爲它從未賺過錢。但它是加密貨幣的另一個玩法。如果你喜歡加密貨幣，就買入加密貨幣。」
On Aug. 14, Core Scientific announced that it increased its offering of convertible senior notes from $350 million to $400 million. The company has also given initial purchasers the option to buy up to an extra $60 million in notes.
8月14日，Core Scientific宣佈將可轉換的優先股發行規模從35000萬美元增加到40000萬美元。該公司還給了初始買家購買多達6000萬美元債券的選擇權。
Price Action:
價格行動：
- Snowflake shares fell 0.2% to settle at $127.05 on Thursday.
- Royalty Pharma shares rose 2.9% to close at $27.41.
- Core Scientific shares gained 5.2% to settle at $9.26 on Thursday.
- Ally Financial shares gained 1.3% to close at $41.61.
- 週四，Snowflake股價下跌0.2％，收於127.05美元。
- 週四，Royalty Pharma的股價上漲2.9％，收於27.41美元。
- 週四，Core Scientific的股價上漲5.2％，收於9.26美元。
- Ally Financial的股價上漲1.3％，收於41.61美元。
- Jim Cramer Recommends Buying Clorox: 'CEO Has Done Remarkable Job'
- 吉姆·克萊默推薦購買高樂氏：'CEO表現出色'